Letter to the editor, Reply to: Lee and Matulonis: Immunotherapy and radiation combinatorial trials in gynecologic cancer: A potential synergy?

Bradley J Monk; Jyoti Mayadev; Ana T Nunes

doi:10.1016/j.gore.2019.100506

Letter to the editor, Reply to: Lee and Matulonis: Immunotherapy and radiation combinatorial trials in gynecologic cancer: A potential synergy?

Gynecol Oncol Rep. 2019 Oct 10:30:100506. doi: 10.1016/j.gore.2019.100506. eCollection 2019 Nov.

Authors

Bradley J Monk^{1

2}, Jyoti Mayadev³, Ana T Nunes⁴

Affiliations

¹ Division of Gynecologic Oncology, Arizona Oncology (US Oncology Network), University of Arizona College of Medicine, Creighton University School of Medicine at St. Joseph's Hospital Phoenix, AZ, USA.
² US Oncology Research Network - Gynecologic Program, 2222 E. Highland Avenue, Suite 400, Phoenix, AZ 85016, USA.
³ Director of Gynecologic Brachytherapy, Chief, Gynecology Oncology Radiation Services, University of California, San Diego, 3855 Health Sciences Drive, La Jolla, CA 92093, USA.
⁴ AstraZeneca, 950 Wind River Ln, Gaithersburg, MD 20878, USA.

Abstract

•CALLA (NCT03830866) is a randomized, international, double-blind, placebo-controlled study.•Immunotherapy-naïve patients with adenocarcinoma or cervical carcinoma are being enrolled.•CALLA is one of the largest trials in this patient population.